Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$27.50
+2.7%		$27.57
$19.69
▼
$30.96
$4.74B0.861.64 million shs803,859 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$247.62
+3.3%		$256.82
$186.05
▼
$282.15
$15.45B0.35684,142 shs794,515 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$11.67
+1.0%		$12.24
$11.36
▼
$15.67
$9.74B0.282.44 million shs2.29 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-2.76%-2.97%-5.24%+23.89%+8.47%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-9.49%-11.23%-3.51%+3.73%+23.20%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-3.07%-2.90%-6.14%-12.21%-21.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$27.50
+2.7%		$27.57
$19.69
▼
$30.96
$4.74B0.861.64 million shs803,859 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$247.62
+3.3%		$256.82
$186.05
▼
$282.15
$15.45B0.35684,142 shs794,515 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$11.67
+1.0%		$12.24
$11.36
▼
$15.67
$9.74B0.282.44 million shs2.29 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-2.76%-2.97%-5.24%+23.89%+8.47%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-9.49%-11.23%-3.51%+3.73%+23.20%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-3.07%-2.90%-6.14%-12.21%-21.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.78
Moderate Buy$34.3624.78% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7525.66% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest ACAD, ASND, and RDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.43$0.89 per share31.02$7.25 per share3.80
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.94N/AN/A($2.97) per share-83.27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.58B2.72$0.83 per share14.06$4.86 per share2.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2212.3928.10N/A33.42%9.03%6.79%11/4/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.0827.76N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$456M$0.4426.4720.432.4810.15%9.49%6.32%10/23/2026 (Estimated)

Latest ACAD, ASND, and RDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
7/23/2026Q1 26/27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.0918$0.06-$0.0318$0.06$850.56 million$850.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.060.52%+6.96%13.64%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.90
1.39

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.31 million127.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,527834.67 million817.98 millionOptionable

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
September 15 at 5:24 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362747/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddy-s-laboratories-limited-rdy.html
Wellington Management Group LLP Cuts Position in Dr. Reddy's Laboratories Ltd $RDY
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-cuts-position-in-dr-reddys-laboratories-ltd-rdy-2026-09-12/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358218/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddy-s-laboratories-limited-rdy.html
Nykredit A S Takes $2 Million Position in Dr. Reddy's Laboratories Ltd $RDY
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-takes-2-million-position-in-dr-reddys-laboratories-ltd-rdy-2026-09-08/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
September 3, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddys-laboratories-limited---rdy-302868540.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354704/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddy-s-laboratories-limited-rdy.html
Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to Hold at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-dr-reddys-laboratories-nyse-rdy-upgraded-to-hold-at-wall-street-zen-2026-08-29/
Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Bank of America Corp DE
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dr-reddys-laboratories-ltd-rdy-shares-sold-by-bank-of-america-corp-de-2026-08-28/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddys-laboratories-limited---rdy-302862236.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350986/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddy-s-laboratories-limited-rdy.html
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/19/10432956.htm
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260819170238/en/securities-fraud-investigation-into-dr.-reddy%e2%80%99s-laboratories-rdy-announced-%e2%80%93-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r.-cruz/
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260813865879/en/rdy-shareholder-alert-dr.-reddy%e2%80%99s-laboratories-investors-encouraged-to-contact-kirby-mcinerney-llp-about-potential-securities-laws-violations/
Dr. Reddy's Laboratories Ltd. Sponsored ADR
August 12, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RDY
Dr. Reddy's Laboratories Launches Sugammadex Injection Single-Dose Vials in US
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dr-reddy-apos-laboratories-launches-092633479.html
DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3339873/937/en/dr-reddy-s-laboratories-investor-alert-kirby-mcinerney-llp-announces-investigation-into-potential-securities-fraud.html
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of ...
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dr-reddy-announces-first-market-053900460.html
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260729613216/en/Dr.-Reddy%E2%80%99s-Announces-the-First-to-Market-Launch-of-Sugammadex-Injection-200-mg2-mL-100-mgmL-and-500-mg5-mL-100-mgmL-Single-Dose-Vials-a-Generic-Equivalent-of-Bridion%C2%AE-in-the-United-States/
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
July 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dr-reddys-laboratories-rdy-securities-investigation-notice---levi--korsinsky-302839636.html
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335383/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-dr-reddy-s-laboratories-rdy.html
Dr Reddys Laboratories Ltd (RDY)
July 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/insider-trading/company/dr+reddys+laboratories+ltd/1135951/news/

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.50 +0.74 (+2.75%)
Closing price 03:59 PM Eastern
Extended Trading
$27.52 +0.03 (+0.11%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$247.62 +7.85 (+3.27%)
Closing price 03:59 PM Eastern
Extended Trading
$245.50 -2.12 (-0.86%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$11.68 +0.14 (+1.17%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas